TP53 and cyclic hematopoiesis: Dismal survival in t-MN calls for various risk-mitigating strategies such as avoidance of avoiding alkylating chemotherapy in patients with low grade NET (associated with long OS), close monitoring of blood counts post-PRRT, and a novel approach of pretreatment and longitudinal screening of CH by identifying premalignant clones with mutant DNA damage response genes (PPM1D and TP53).